To include your compound in the COVID-19 Resource Center, submit it here.

MycoVa: Additional Phase III data

A post hoc analysis of the double-blind Phase III N2301 and N2302 trials in 1,044 patients with mild to moderate nail fungus showed once-daily MycoVa significantly increased mycological cure rate in patients

Read the full 321 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE